This Biopharma Offspring Is All Grown Up

One of the most memorable Abbott moments under former CEO Miles White, was the company's AbbVie spinoff in 2012.

Today, AbbVie is larger than Abbott, with a market cap of over $285 billion. The company produces about 26 drugs, including Imbruvica, Lupron, and Humira, which accounts for roughly 37% of its revenues. In 2019, AbbVie shelled out $63 billion to acquire Allergan, the manufacturer of Botox.